Evidence map›Paper›PMID 36310321›Full record

ArticleCommunications biology2022

Honing-in antigen-specific cells during antibody discovery: a user-friendly process to mine a deeper repertoire.

Ankit Mahendra, Aftabul Haque, Ponraj Prabakaran, Brian C Mackness, Thomas P Fuller, Xiaohua Liu, Sagar V Kathuria, Yui-Hsi Wang, Nilesh Amatya, Xiaocong Yu and 11 more

Abstract read
In one paragraph

Article in Communications biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Lymphoid-Tissue-on-Chip Recapitulates Human Antibody Responses In Vitro.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Ankit Mahendra *Large Molecule Research, Sanofi, 49 New York Avenue, Framingham, MA, USA. ankit.mahendra@sanofi.com.ORCID 0000-0002-6664-5974
Aftabul Haque *Large Molecule Research, Sanofi, 49 New York Avenue, Framingham, MA, USA.
Ponraj PrabakaranLarge Molecule Research, Sanofi, 49 New York Avenue, Framingham, MA, USA.ORCID 0000-0002-4049-4813
Brian C MacknessLarge Molecule Research, Sanofi, 49 New York Avenue, Framingham, MA, USA.
Thomas P FullerLarge Molecule Research, Sanofi, 49 New York Avenue, Framingham, MA, USA.
Xiaohua LiuLarge Molecule Research, Sanofi, 49 New York Avenue, Framingham, MA, USA.
Sagar V KathuriaLarge Molecule Research, Sanofi, 49 New York Avenue, Framingham, MA, USA.ORCID 0000-0003-3670-4467
Yui-Hsi WangImmunology & Inflammation Research, Genomics Center, Sanofi, 270 Albany Street, Cambridge, MA, USA.
Nilesh AmatyaImmunology & Inflammation Research, Genomics Center, Sanofi, 270 Albany Street, Cambridge, MA, USA.
Xiaocong YuLarge Molecule Research, Sanofi, 49 New York Avenue, Framingham, MA, USA.
Joern HopkeMolecular Expression and Screening Technologies, Sanofi, 270 Albany Street, Cambridge, MA, USA.
Dietmar HoffmannMolecular Expression and Screening Technologies, Sanofi, 270 Albany Street, Cambridge, MA, USA.
Eva Bric-FurlongMolecular Expression and Screening Technologies, Sanofi, 270 Albany Street, Cambridge, MA, USA.
Ningning ZhangLarge Molecule Research, Sanofi, 49 New York Avenue, Framingham, MA, USA.
Hyun-Suk ChoLarge Molecule Research, Sanofi, 49 New York Avenue, Framingham, MA, USA.
Ruijun ZhangLarge Molecule Research, Sanofi, 49 New York Avenue, Framingham, MA, USA.ORCID 0000-0002-6872-7850
Jose SanchoNeuroinflammation, Sanofi Genzyme, 49 New York Avenue, Framingham, MA, USA.
Jacqueline SalehNeuroinflammation, Sanofi Genzyme, 49 New York Avenue, Framingham, MA, USA.
Sambasiva P RaoLarge Molecule Research, Sanofi, 49 New York Avenue, Framingham, MA, USA.
Maria WendtLarge Molecule Research, Sanofi, 49 New York Avenue, Framingham, MA, USA.
Partha S ChowdhuryLarge Molecule Research, Sanofi, 49 New York Avenue, Framingham, MA, USA. pchowd15@its.jnj.com.ORCID 0000-0003-0990-4658

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunization based antibody discovery is plagued by the paucity of antigen-specific B cells. Identifying these cells is akin to finding needle in a haystack. Current and emerging technologies while effective, are limited in terms of capturing the antigen-specific repertoire. We report on the bulk purification of antigen-specific B-cells and the benefits it offers to various antibody discovery platforms. Using five different antigens, we show hit rates of 51-88%, compared to about 5% with conventional methods. We also show that this purification is highly efficient with loss of only about 2% antigen specific cells. Furthermore, we compared clones in which cognate chains are preserved with those from display libraries in which chains either from total B cells (TBC) or antigen-specific B cells (AgSC) underwent combinatorial pairing. We found that cognate chain paired clones and combinatorial clones from AgSC library had higher frequency of functional clones and showed greater diversity in sequence and paratope compared to clones from the TBC library. This antigen-specific B-cell selection technique exemplifies a process improvement with reduced cycle time and cost, by removing undesired clones prior to screening and increasing the chance of capturing desirable and rare functional clones in the repertoire.

Indexed as

AntibodiesImmunizationBinding Sites, AntibodyEpitopesGene LibraryAntibodiesEpitopes

Identifiers

PMID36310321
PMCPMC9618561

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.